A Phase 1 interventional study of Ped-TMZ in Therapeutic Equivalency, sponsored by Orphelia Pharma. Completed at 3 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-02-23.
Sponsored by Orphelia Pharma · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Primary objective:
Secondary objectives:
The study is an open label, randomized, crossover, 2-period study in 30 male/female patients with primary CNS malignancies. Patients will receive, under fasting conditions, 200 mg/m² of Temozolomide Oral Suspension (Ped-TMZ) or Temodal®, as single oral administration in 2 different study periods depending on the randomization, with no wash out period between administrations.
Orphelia Pharma is the lead sponsor of 4 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single oral administration on D1 or D2 according to randomization at the dose of 200 mg/m2. Ped-TMZ will be administered using the provided dosing oral syringes and followed by a glass of 240 ml of water (for mouth rinsing) in sitting position and under fasting condition.
Drug: Ped-TMZ
Single oral administration on D1 or D2 according to randomization at the dose of 200 mg/m2. The administration will take place around 8:00 a.m. followed with 240 mL of tap water, in sitting position and under fasting condition
Drug: Ped-TMZ
Ped-TMZ will be administered using the provided dosing oral syringes and followed by a glass of 240 ml of water (for mouth rinsing) in sitting position and under fasting condition for at least 8 hours before dosing
Also known as: Temozolomide Oral Suspension
Primary pharmacokinetic parameter: Cmax
The Cmax pharmacokinetic parameter will be determined from temozolomide plasma concentrations
Time frame: Day 1 or Day 2
Primary pharmacokinetic parameter: AUC0-t
The AUC0-t pharmacokinetic parameter will be determined from temozolomide plasma concentrations
Time frame: Day 1 or Day 2
Secondary pharmacokinetic parameter: AUC0-inf
The AUC0-inf pharmacokinetic parameter will be determined from temozolomide plasma concentrations
Time frame: Day 1 or Day 2
Secondary pharmacokinetic parameter: tmax
The tmax pharmacokinetic parameter will be determined from temozolomide plasma concentrations
Time frame: Day 1 and Day 2
Secondary pharmacokinetic parameter: λ
The λ pharmacokinetic parameter will be determined from temozolomide plasma concentrations
Time frame: Day 1 and Day 2
Secondary pharmacokinetic parameter: t1/2
The t1/2 pharmacokinetic parameters will be determined from temozolomide plasma concentrations
Time frame: Day 1 and Day 2
Secondary pharmacokinetic parameter: residual area
The residual area of temozolomide will be determined from temozolomide plasma concentrations
Time frame: Day 1 and Day 2
Plan to share: No
No publications or documents are linked to this record.
Ran from Sep 2020 to primary completion in Dec 2021, 14 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Temozolomide
Orphelia Pharma